# US 2012/0251571 A1 · Rnase l-mediated cleavage products and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251571 A1
- Document ID: US20120251571A1
- Status: Published application
- Kind: A1
- Application number: 13/247,961
- Filed: 2011-09-28
- Published: 2012-10-04
- Earliest claimed: 2010-09-28
- Assignees: The Cleveland Clinic Foundation
- Inventors: Robert H. Silverman; Malathi Krishnamurthy
- Web page: https://patentgrep.com/patent/US20120251571A1

## CPC

- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61P 31/14: for RNA viruses
- A61P 37/04: Immunostimulants
- C12N 15/117: Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- C12N 2310/17: Immunomodulatory nucleic acids
- C12N 2310/53: partially self-complementary or closed
- C12N 2330/00: Production
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention is directed to one or more RNase L mediated cleavage products. In particular aspects, the RNase L mediated cleavage products are RNase L mediated cleavage products of a virus, referred to herein as a “suppressor of virus ribonucleic acid (RNA)” or “svRNA” and uses thereof.

## Claims

### Claim 1

An isolated nucleic acid sequence comprising SEQ ID NO: 1.

### Claim 2 (depends on 1)

The sequence of claim 1 further comprising one or more hydroxyl (—OH) groups, one or more monophosphoryl (-p) groups, one or more single stranded overhangs or a combination thereof.

### Claim 3 (depends on 2)

The sequence of claim 2 further comprising a 5′-OH and a 3′-p.

### Claim 4 (depends on 2)

The sequence of claim 2 further comprising a 5′-p3 and a 3′-OH.

### Claim 5 (depends on 2)

The sequence of claim 2 further comprising a 5′ single stranded overhang, a 3′ single stranded overhang or a combination thereof.

### Claim 6

An isolated nucleic acid sequence comprising SEQ ID NO: 25.

### Claim 7

An isolated nucleic acid sequence comprising SEQ ID NO: 26.

### Claim 8 (depends on 1)

A pharmaceutical composition comprising the sequence of claim 1.

### Claim 9 (depends on 6)

A pharmaceutical composition comprising the sequence of claim 6.

### Claim 10 (depends on 7)

A pharmaceutical composition comprising the sequence of claim 7.

### Claim 11

A method of inducing an immune response to a hepatitis C virus (HCV) in a cell comprising introducing into the cell a composition comprising a HCV svRNA; and maintaining the cell under conditions in which the svRNA stimulates RIG-1 signaling and propagates signaling to the IFN-β gene, thereby inducing an immune to the HCV in the cell.

### Claim 12 (depends on 11)

The method of claim 11 wherein the composition comprises SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27 or a combination thereof.

### Claim 13 (depends on 11)

The method of claim 11 wherein the cell is a mammalian cell.

### Claim 14 (depends on 13)

The method of claim 13 wherein the mammalian cell is a human cell.

### Claim 15 (depends on 11)

The method of claim 11 wherein the HCV is genotype 1a HCV.

### Claim 16

A method of inducing an immune response to HCV in an individual in need thereof comprising administering a therapeutically effective amount of a composition comprising a HCV svRNA that stimulates RIG-1 signaling and propagates signaling to the IFN-β gene, thereby inducing an immune response to the HCV in the individual.

### Claim 17 (depends on 16)

The method of claim 16 wherein the composition comprises SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27 or a combination thereof.

### Claim 18 (depends on 16)

The method of claim 16 wherein the individual is a mammal.

### Claim 19 (depends on 18)

The method of claim 18 wherein the mammal is a human.

### Claim 20 (depends on 16)

The method of claim 16 wherein the HCV is genotype 1a HCV.

### Claim 21

A method of treating a HCV in an individual in need thereof comprising administering a therapeutically effective amount of a composition comprising a HCV svRNA (e.g., HCV svRNA3) that stimulates RIG-1 signaling and propagates signaling to the IFN-β gene, thereby inducing an immune response to the HCV in the individual.

### Claim 22 (depends on 21)

The method of claim 21 wherein the composition comprises SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27 or a combination thereof.

### Claim 23 (depends on 21)

The method of claim 21 wherein the individual is a mammal.

### Claim 24 (depends on 23)

The method of claim 23 wherein the mammal is a human.

### Claim 25 (depends on 21)

The method of claim 21 wherein the HCV is genotype 1a HCV.
